Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin
LS Czer,
TM Bateman,
RJ Gray,
M Raymond,
ME Stewart,
S Lee,
D Goldfinger,
A Chaux,
and
JM Matloff
Impairment of platelet function commonly occurs after cardiopulmonary bypass, and may result in substantial bleeding. Because desmopressin acetate (a synthetic analogue of vasopressin) shortens bleeding time in a variety of platelet disorders, a controlled clinical trial of intravenous desmopressin was performed in 39 patients with excessive mediastinal bleeding (greater than 100 ml/h) and a prolonged template bleeding time (greater than 10 minutes) more than 2 hours after termination of cardiopulmonary bypass. Twenty-three desmopressin recipients and 16 control patients (no desmopressin) were similar in surgical procedure, pump time, platelet count, template bleeding time and amount of bleeding before therapy (p = NS). Compared with the control group, the patients receiving desmopressin (20 micrograms; mean 0.3 micrograms/kg) utilized fewer blood products (29 +/- 19 versus 15 +/- 13 units/patient; p less than 0.05), especially platelets (12 +/- 9 versus 4 +/- 7 units/patient; p = 0.004), while achieving a similarly effective reduction in mediastinal bleeding (4.8- and 4.3-fold, p = 0.001 for both). Severe platelet dysfunction was partially corrected within 1 hour after desmopressin infusion, during which interval no blood products were administered: the template bleeding time shortened (from 17 to 12.5 minutes, p less than 0.05), whereas the platelet count remained unchanged (at 96 +/- 35 and 105 +/- 31 X 10(3)/mm3, p = NS). The plasma levels of two factor VIII components increased: procoagulant activity (VIII:C) from 0.97 +/- 0.43 to 1.52 +/- 0.74 units/ml (p less than 0.05) and von Willebrand factor (VIII:vWF) from 1.28 to 1.78 units/ml (p less than 0.05); these increases correlated with the shortening of the bleeding time (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
|
|
 
E. Ozal, E. Kuralay, H. Bingol, F. Cingoz, S. Ceylan, and H. Tatar
Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis?
J. Thorac. Cardiovasc. Surg.,
March 1, 2002;
123(3):
539 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Skubas and G. J. Despotis
Optimal Management of Bleeding Complications After Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia,
September 1, 2001;
5(3):
217 - 228.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. C. Oliver Jr, P. J. Santrach, G. K. Danielson, G. A. Nuttall, D. R. Schroeder, and M. H. Ereth
Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations
Ann. Thorac. Surg.,
December 1, 2000;
70(6):
1923 - 1930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-O. Defraigne, J. Pincemail, G. Dekoster, R. Larbuisson, M. Dujardin, F. Blaffart, J.-L. David, and R. Limet
SMA circuits reduce platelet consumption and platelet factor release during cardiac surgery
Ann. Thorac. Surg.,
December 1, 2000;
70(6):
2075 - 2081.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Despotis and L. T. Goodnough
Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery
Ann. Thorac. Surg.,
August 1, 2000;
70(2):
S20 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Casas, I. Zuazu-Jausoro, J. Mateo, A. Oliver, H. Litvan, E. Muniz-Diaz, A. Aris, J. M. Caralps, and J. Fontcuberta
APROTININ VERSUS DESMOPRESSIN FOR PATIENTS UNDERGOING OPERATIONS WITH CARDIOPULMONARY BYPASS: A double-blind placebo-controlled study
J. Thorac. Cardiovasc. Surg.,
October 1, 1995;
110(4):
1107 - 1117.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. V. Arom and R. W. Emery
Decreased postoperative drainage with addition of {epsilon}-aminocaproic acid before cardiopulmonary bypass
Ann. Thorac. Surg.,
May 1, 1994;
57(5):
1108 - 1113.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. J. Ray, G. A. T. Hawson, S. J. E. Just, G. McLachlan, and M. O'Brien
Relationship of platelet aggregation to bleeding after cardiopulmonary bypass
Ann. Thorac. Surg.,
April 1, 1994;
57(4):
981 - 986.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Lethagen
Desmopressin (DDAVP), tranexamic acid and haemostasis
Perfusion,
September 1, 1993;
8(5):
417 - 425.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. D Weisel
Agents that modify haemostasis after cardiopulmonary bypass
Perfusion,
May 1, 1993;
8(1_suppl):
6 - 12.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. M Cosgrove
Use of aprotinin in repeat myocardial revascularization: Cleveland Clinic experience
Perfusion,
May 1, 1993;
8(1_suppl):
36 - 42.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. W. Salzman, M. J. Weinstein, D. Reilly, and J. A. Ware
Adventures in Hemostasis: Desmopressin in Cardiac Surgery
Arch Surg,
February 1, 1993;
128(2):
212 - 217.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. K. Spence
Transfusion Practices in Vascular Surgery
Perspectives in Vascular Surgery and Endovascular Therapy,
January 1, 1993;
6(2):
14 - 43.
[PDF]
|
|
|
|
|
|
|
C. P. Ratnatunga, G. M. Rees, and I. B. Kovacs
Preoperative hemostatic activity and excessive bleeding after cardiopulmonary bypass
Ann. Thorac. Surg.,
August 1, 1991;
52(2):
250 - 257.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Johnson, A. E. Gundersen, I. D. Stickney, and T. H. Cogbill
Selective approach to sternal closure after exploration for hemorrhage following coronary artery bypass
Ann. Thorac. Surg.,
May 1, 1990;
49(5):
771 - 774.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Spyt, N. Weerasena, W. Bain, G. Lowe, and A. Rumley
The effects of desmopressin acetate (DDAVP) on haemostasis and blood loss in routine coronary artery bypass surgery: a randomized, double-blind trial I
Perfusion,
January 1, 1990;
5(1_suppl):
57 - 61.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. G. Copeland III, L. A. Harker, J. H. Joist, and W. C. DeVries
Panel 3 Bleeding and anticoagulation
Ann. Thorac. Surg.,
January 1, 1989;
47(1):
88 - 95.
[PDF]
|
|
|
|
|
|
|
B. P Bidstrup
Review article : Blood conservation in cardiac surgery: can drugs help?
Perfusion,
July 1, 1988;
3(3):
171 - 177.
[PDF]
|
|
|
|
